Articles in Scholarly Journals [Incomplete List]

1. PPARs/RXRs in Cardiovascular Physiology and Disease
   PPAR Research, vol. 2008, Article ID 173780, 1 pages, 2008
2. Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists
   Molecular Human Reproduction, vol. 13, no. 6, pp. 373–379, 2007
3. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors
   Nature Clinical Practice Endocrinology & Metabolism, vol. 3, no. 2, Article ID ncpendmet0397, 11 pages, 2007
4. Safety issues and prospects for future generations of PPAR modulators
   Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 1065–1081, 2007
5. IP receptor-dependent activation of PPAR? by stable prostacyclin analogues
   Biochemical and Biophysical Research Communications, vol. 360, no. 4, pp. 821–827, 2007
6. PPARd, but not PPARa, activates PGC-1a gene transcription in muscle
   Biochemical and Biophysical Research Communications, vol. 354, no. 4, pp. 1021–1027, 2007
7. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor a agonists
   Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 16, pp. 4689–4693, 2007
8. PPAR? Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties
   Cell Metabolism, vol. 6, no. 2, pp. 137–143, 2007
9. The core component of the mammalian SWI/SNF complex SMARCD3/BAF60c is a coactivator for the nuclear retinoic acid receptor
   Molecular and Cellular Endocrinology, vol. 270, no. 1-2, pp. 23–32, 2007
10. FXR: a promising target for the metabolic syndrome?
    Trends in Pharmacological Sciences, vol. 28, no. 5, pp. 236–243, 2007
11. The PPAR?? Activator Fenofibrate Slows Down the Progression of the Left Ventricular Dysfunction in Porcine Tachycardia-Induced Cardiomyopathy
    Journal of Cardiovascular Pharmacology, vol. 49, no. 6, pp. 408–415, 2007
12. IAP Survivin Regulates Atherosclerotic Macrophage Survival
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 901–907, 2007
13. The orphan nuclear receptor Rev-erb??: a transcriptional link between circadian rhythmicity and cardiometabolic disease
    Current Opinion in Lipidology, vol. 18, no. 2, p. 141???146, 2007
14. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control
    Current Opinion in Lipidology, vol. 18, no. 3, p. 289???297, 2007
15. Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins
    Circulation Research, vol. 100, no. 10, pp. 1394–1395, 2007
16. Liver X Receptor Activation Potentiates the Lipopolysaccharide Response in Human Macrophages
    Circulation Research, vol. 101, no. 1, pp. 40–49, 2007
17. Retinoid-related orphan receptor   regulates several genes that control metabolism in skeletal muscle cells: links to modulation of reactive oxygen species production
    Journal of Molecular Endocrinology, vol. 39, no. 1, pp. 29–44, 2007
18. Bile???Acid???Sequestrants???and???the???Treatment of Type??2??Diabetes??Mellitus
    Drugs, vol. 67, no. 10, pp. 1383–1392, 2007
19. PPAR  Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes
    Diabetes, vol. 56, no. 6, pp. 1662–1670, 2007
20. Genetically-engineered animals as research models for atherosclerosis : their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders
    Frontiers in Bioscience, vol. 12, no. 8-12, p. 4132, 2007
21. Inter-subject differences in constitutive expression levels of the clock gene in man.
    Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, vol. 4, no. 1, p. 39, 2007
22. Transcription Factor TCF7L2 Genetic Study in the French Population: Expression in Human  -Cells and Adipose Tissue and Strong Association With Type 2 Diabetes
    Diabetes, vol. 55, no. 10, pp. 2903–2908, 2006
23. Peroxisome Proliferator-Activated Receptor � Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets
    Diabetes, vol. 55, no. 6, pp. 1605–1613, 2006
24. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis
    Expert Opinion on Emerging Drugs, vol. 11, no. 3, pp. 379–401, 2006
25. Peroxisome Proliferator-Activated Receptor   and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism
    Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 2, pp. 386–395, 2006
26. Metformin and pioglitazone: effectively treating insulin resistance
    Current Medical Research and Opinion, vol. 22, no. 1, pp. 27–37, 2006
27. FXR: More than a Bile Acid Receptor?
    Endocrinology, vol. 147, no. 9, pp. 4022–4024, 2006
28. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo
    Journal of Clinical Investigation, vol. 116, no. 4, pp. 1052–1062, 2006
29. Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-  Activators: Clinical and Experimental Evidence
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 5, pp. 977–986, 2006
30. The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 12, pp. 2731–2737, 2006
31. Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients: Data From a Randomized Placebo-Controlled Trial
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 4, pp. 845–850, 2006
32. Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator-Activated Receptor-? via Inhibition of the Protein Kinase C Signaling Pathway
    Circulation Research, vol. 98, no. 3, pp. 361–369, 2006
33. Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo
    Circulation, vol. 114, no. 12, pp. 1301–1309, 2006
34. Cholesterol 7 -Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Increases Hepatic ABCA1 mRNA Expression and HDL-Cholesterol
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 12, pp. 2724–2730, 2006
35. Sorting out the roles of PPAR? in energy metabolism and vascular homeostasis
    Journal of Clinical Investigation, vol. 116, no. 3, pp. 571–580, 2006
36. TReP-132 Is a Novel Progesterone Receptor Coactivator Required for the Inhibition of Breast Cancer Cell Growth and Enhancement of Differentiation by Progesterone
    Molecular and Cellular Biology, vol. 26, no. 20, pp. 7632–7644, 2006
37. Human retinoic acid receptor-related orphan receptor ?1 overexpression protects neurones against oxidative stress-induced apoptosis
    Journal of Neurochemistry, vol. 96, no. 6, pp. 1778–1789, 2006
38. Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPAR? agonists
    Bioorganic & Medicinal Chemistry, vol. 14, no. 22, pp. 7377–7391, 2006
39. Studies towards the conception of new selective PPARß/d ligands
    Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 17, pp. 4528–4532, 2006
40. Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
    Journal of the American College of Cardiology, vol. 48, no. 9, pp. A24–A32, 2006
41. The expanding role of the bile acid receptor FXR in the small intestine
    Journal of Hepatology, vol. 44, no. 6, pp. 1213–1215, 2006
42. PPARa and PPAR? dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
    Current Opinion in Pharmacology, vol. 6, no. 6, pp. 606–614, 2006
43. Transcriptional regulation of macrophage cholesterol trafficking by PPARa and LXR
    Biochemical Society Transactions, vol. 34, no. 6, p. 1128, 2006
44. When the Clock stops ticking, metabolic syndrome explodes
    Nature Medicine, vol. 12, no. 1, Article ID nm0106-54, 1 pages, 2006
45. Niemann–Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine
    Biochemical and Biophysical Research Communications, vol. 340, no. 4, pp. 1259–1263, 2006
46. The liver X-receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice
    Hepatology, vol. 44, no. 2, pp. 368–378, 2006
47. [4-(2H-1,2,3-Benzotriazol-2-yl)phenoxy]alkanoic Acids as Agonists of Peroxisome Proliferator-Activated Receptors (PPARs)
    Chemistry & Biodiversity, vol. 3, no. 4, pp. 385–395, 2006
48. Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c
    Journal of Biological Chemistry, vol. 281, no. 10, pp. 6211–6218, 2006
49. The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice
    Journal of Biological Chemistry, vol. 281, no. 16, pp. 11039–11049, 2006
50. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
    Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006
51. Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms
    Journal of Cardiovascular Pharmacology, vol. 47, no. 4, pp. 599–608, 2006
52. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases
    Biochemical Society Transactions, vol. 34, no. 6, p. 1341, 2006
53. A fully dissociated compound of plant origin for inflammatory gene repression
    Proceedings of the National Academy of Sciences, vol. 102, no. 44, pp. 15827–15832, 2005
54. The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2020–2030, 2005
55. TReP-132 Controls Cell Proliferation by Regulating the Expression of the Cyclin-Dependent Kinase Inhibitors p21WAF1/Cip1 and p27Kip1
    Molecular and Cellular Biology, vol. 25, no. 11, pp. 4335–4348, 2005
56. Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor
    Molecular and Cellular Biology, vol. 25, no. 4, pp. 1537–1548, 2005
57. The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition
    Journal of Biological Chemistry, vol. 280, no. 33, pp. 29971–29979, 2005
58. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy
    Current Opinion in Pharmacology, vol. 5, no. 2, pp. 177–183, 2005
59. Fluid retention mediated by renal PPAR
    Cell Metabolism, vol. 2, no. 2, pp. 77–78, 2005
60. Pro-inflammatory properties for thiazolidinediones
    Biochemical Pharmacology, vol. 69, no. 2, pp. 255–265, 2005